News Center
Livzon has been awarded the highest MSCI ESG global rating of AAA.
Release time:
2024-08-05
Recently, the international authoritative index companyMSCI(Morgan Stanley Capital International, Morgan Stanley Capital International Company) announced the latest annualESG(Environmental,Social and Governance, that is, environmental, social and governance) rating results,2024the annual rating of LijunMSCI ESGhas maintained the highest global ratingAAAlevel.
As of the date of this rating update, in the global pharmaceutical industry (a total of250companies evaluated) only6companies have obtainedMSCI ESGthe highest rating.AAAApart from Lijun, the others are Germany's Merck, Denmark's Novo Nordisk, the United States' Merck, Japan's Daiichi Sankyo, and Japan's AstraZeneca. Lijun is the first and only Chinese company in the global pharmaceutical industry to obtain5MSCI AAArating, and also the only company in the Chinese pharmaceutical industry to have receivedthe rating for two consecutive years.rating, and also the only company in the Chinese pharmaceutical industry to have receivedIn addition, in June this year, Lijun was awarded
Wind ESGratingAlevel, and has maintained this for three consecutive years.level, and has maintained this for three consecutive years.The comprehensive score of Wind ESGlevel, and has maintained this for three consecutive years.level, and has maintained this for three consecutive years.level.is composed of management practices and controversy events, the rating framework aligns with international mainstreamsystem architecture while fully considering the current situation of the Chinese capital market, regulatory policies, and the specificESGpractices of Chinese enterprises. Currently,ESGthe rating has covered all ESGratingA-shares, Hong Kong-listed companies, and important bond issuers, aboutlevel, and has maintained this for three consecutive years.10,000+companies.Lijun has always selectively and gradually implemented improvement actions based on the characteristics of the pharmaceutical industry and its own actual situation. In terms of governance, Lijun has always attached great importance to
ESGmanagement work, establishing a governance structure with the board of directors as the highest decision-making body, and incorporatingassessment indicators into the personal performance evaluation of working group members, building a compensation mechanism linked to sustainable development. In terms of the environment, Lijun actively implements the concept of green low-carbon operation, taking measures such as energy conservation and emission reduction, steadily moving towards the goal ofcarbon neutrality by 2030.ESGIn terms of society, Lijun always adheres to a people-oriented approach, allowing employees to grow in an equal, respectful, inclusive, and diverse working environment; actively carrying out public welfare activities such as chronic disease prevention and rural revitalization, practicing corporate social responsibility. Lijun upholds the mission of "patient quality of life first," promoting inclusive health and public health as the original intention of corporate operations, continuously focusing on unmet clinical needs, steadily advancing product innovation, enhancing product accessibility and affordability, and allowing high-quality products to benefit more people globally.ESGThrough continuousESGgovernance improvement, Lijun has gained widespread recognition and affirmation from society and rating agencies. In addition to2055the rating continuously improving rapidly, Lijun was also selected this year for S&P Global's "Sustainability Yearbook
" and "Sustainability YearbookESG(China Edition)," and received S&P's award for the annual global pharmaceutical industry's only "Best Progress Company" and the annual Chinese pharmaceutical industry's only "Best Progress Company" recognition.MSCI ESG、is composed of management practices and controversy events, the rating framework aligns with international mainstream评级持续快速提升外，丽珠在今年还分别入选了标普全球《可持续发展年鉴2024》和《可持续发展年鉴2024（中国版）》，并获得标普颁布的2023年度全球制药行业唯一的“行业最佳进步企业”和2023年度中国制药行业唯一的“行业最佳进步企业”表彰。
Related Information